Context Therapeutics (NASDAQ:CNTX) Stock Rating Lowered by Zacks Research

Context Therapeutics (NASDAQ:CNTX) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday, Zacks reports.

Several other equities research analysts also recently weighed in on the stock. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Weiss Ratings downgraded Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Finally, Maxim Group reduced their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $0.28 on Monday. Context Therapeutics has a one year low of $0.27 and a one year high of $3.62. The company’s 50-day moving average is $0.40 and its 200 day moving average is $1.22. The company has a market capitalization of $25.27 million, a price-to-earnings ratio of -0.57 and a beta of 1.71.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). As a group, research analysts predict that Context Therapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new stake in Context Therapeutics in the 2nd quarter worth approximately $29,000. Two Sigma Securities LLC raised its stake in Context Therapeutics by 388.7% during the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock valued at $34,000 after buying an additional 48,871 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Context Therapeutics during the 2nd quarter valued at $30,000. ADAR1 Capital Management LLC bought a new position in shares of Context Therapeutics during the 2nd quarter valued at $416,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Context Therapeutics during the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.